A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2018
Price : $35 *
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications Hepatitis C; HIV-1 infections
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 16 Nov 2016 Status changed from active, no longer recruiting to completed.
- 11 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Sep 2016.
- 11 May 2016 Results (n = 72) published in the JAIDS.